Health-Related Quality of Life (HRQoL) of Adult Filipinos with Graves’ Disease cured by Radioiodine Therapy compared to those controlled by Antithyroid Drugs at University of Santo Tomas Hospital: A Pilot Study

Authors

  • Sheila Farisha Mangelen University of Santo Tomas Hospital
  • Elaine Cunanan University of Santo Tomas Hospital

Keywords:

Graves’ disease, quality of life, radioactive iodine, antithyroid drug

Abstract

Objective.The study aims to develop and validate the Filipino version of Thyroid-disease specific quality of life Patient Reported Outcome (ThyPROph) questionnaire, and to conduct a pilot study comparing the quality of life of patients with Graves’ disease at University of Santo Tomas Hospital (USTH) after receiving radioactive iodine ablation (RAI) or anti-thyroid drug (ATD) using the validated ThyPROph.

Methodology. This study has 2 phases. Phase 1 is the development and validation of the ThyPROph with prior translation and pretesting to Graves’ disease patients. Phase 2 is the pilot study involving 58 euthyroid patients with Graves’ disease recruited to answer the validated ThyPROph. All of the participants completed the ThyPROph. A cross sectional comparative design was used to compare health-related quality of life (HRQoL) under two modes of treatment for Graves’ disease: RAI and ATD. Likewise, correlation of the domains with the demographics was determined using Pearson correlation coefficient and Spearman rank signed test.

Results. For the phase 1 study, internal consistency exists across all domains of ThyPROph with Cronbach’s alpha of 0.839. Overall, discriminant validity falls within range of 0.028-0.606 and convergent validity showed moderate correlations. Phase 2 study showed that there is a significant difference in the domains “goiter symptoms” (p=0.0209), “emotional susceptibility” (p=0.0067) and “impaired daily life” (p=0.0463). The HRQoL is significantly better in the RAI group based on these three domains. Statistically significant correlations exist between goiter grade and goiter symptoms domain (p=0.0001), gender and impaired daily life domain (p=0.016), cosmetic complaints domain with age (p=0.002), marital status (p=0.046), and disease duration (p=0.005).

Limitations. Results are not powered to achieve the primary objective because complications of Graves’ disease were excluded. The reliability of the domains is reduced. A prospective randomized study is more ideal.

Conclusion. Quality of life of patients with Graves’ disease as assessed by ThyPROph is significantly better with RAI compared to ATD. RAI therapy can be considered as the better treatment option in our setting especially for patients who have noticeable goiters with symptoms attributable to their goiters, and those with emotional instability.

Downloads

Download data is not yet available.

Author Biographies

Sheila Farisha Mangelen, University of Santo Tomas Hospital

Department of Medicine-Section of Endocrinology, Diabetes and Metabolism, Fellow-in-Training

Elaine Cunanan, University of Santo Tomas Hospital

Department of Medicine-Section of Endocrinology, Diabetes and Metabolism, Consultant

References

Melmed S, Polonsky KS, Larsen PR, Kronenberget. William’s Endocrinology. 13th edition. Philadelphia: Elsevier, 2016.

Harper MB, Mayeaux EJ Jr. Thyroid disease, 6th ed. New York: Springer, 2003.

Bukvic B, Zivaljevic V, Sipetic S, et al. Improved quality of life in hyperthyroidism patients after surgery. J Surg Res. 2015;193(2):724-30. PMID: 25167783. https://doi.org/10.1016/j.jss.2014.07.061.

Tütüncü NB, Tütüncü T, Ozgen A, et al. Long-term outcome of Graves' disease patients treated in a region with iodine deficiency: Relapse rate increases in years with thionamides. J Natl Med Assoc. 2006; 98(6):926-30. PMCID: PMC2569379.

Watt T, Hegedüs L, Rasmussen AK, et al. Which domains of thyroid-related quality of life are most relevant? Patients and clinicians provide complementary perspectives. Thyroid. 2007;17(7):647-55. https://doi.org/10.1089/thy.2007.0069.

Leslie WD, Ward L, Salamon EA, Ludwig S, Rowe RC, Cowden EA. A randomized comparison of radioiodine doses in Graves' hyperthyroidism. J Clin Endocrinol Metab. 2003;88 (3) :978-83. PMID: 12629071. https://doi.org/10.1210/jc.2002-020805.

Bartalena L, Marcocci C, Bogazzi F, et al. Relation between therapy for hyperthyroidism and the course of Graves’ ophthalmopathy. New Engl J Med. 1998;338(2):73-8. PMID: 9420337 https://doi.org/10.1056/NEJM199801083380201.

Kasper DL, Hausen SL, Jameson JL, Fauci AS, Longo DL, Loscalzo J. Harrison’s Principles of Internal Medicine, 19th ed. United States: McGraw-Hill Education, 2015.

Torring O, Tallstedt L, Wallin G, et al. Graves’ hyperthyroidism: Treatment with antithyroid drugs, surgery, or radioiodine-a prospective, randomized study. J Clin Endocrinol Metabol. 1996;81(8):2986-93. PMID: 8768863. https://doi.org/ 10.1210/jcem.81.8.8768863.

Watt T, Barbesino G, Bjorner JB, et al. Cross- cultural validity of the thyroid-specific quality-of-life patient-reported outcome measure, ThyPRO. Qual Life Res. 2015;24 (3):769-80. PMID: 25194574. https://doi.org/10.1007/s11136-014-0798-1.

Ware JE Jr, Gandek B. Overview of the SF-36 Health Survey and the International Quality of Life Assessment (IQOLA) Project. J Clin Epidemiol. 1998;51(11):903-12. PMID: 9817107.

Li RJ, Jimeno C, Sandoval MA, et al. Development and validation of a thyroid cancer-specific health-related Quality of Life questionnaire for adult Filipinos with differentiated thyroid cancer. J ASEAN Fed Endocr Soc. 2016;31(2):87-93. https://doi.org/10.15605/jafes.031.02.03.

Watt T, Hegedüs L, Groenvold M, et al. Validity and reliability of the novel thyroid-specific quality of life questionnaire, ThyPRO. Eur J Endocrinol. 2010;162(1):161–7. PMID: 19797502. https://doi.org/10.1530/EJE-09-0521.

Cuison R, Mercado-Asis. Thyroid Handbook, 1st ed. Philippines: Goodwill Trading Co., Inc., 2004.

Ceccarelli C, Canale D, Vitti P. Radioactive iodine (131I) effects on male fertility. Curr Opin Urol. 2008;18(6):598-601. PMID: 18832945. https://doi.org/10.1097/MOU.0b013e32831367b3.

Yaish I, Azem F, Serebro M, et al. High dose radioiodine therapy affects ovarian reserve in women with differentiated thyroid cancer. Oral presentation at: ENDO 2016; April 1-4, 2016; Boston, Massachusetts. Abstract OR22-6.

Abcede A, Kho S, Matawaran B, Mercado-Asis LB. Significant reduction in the size of cystic thyroid nodules with ^131Iodine Therapy. JEM. 2014;4 (3):12-8.

Weetman A. Radioiodine treatment for benign thyroid diseases. Clin Endocrinol. 2007;66(6):757–64. https://doi.org/10.1111/j.1365-2265.2007.02841.x.

Vitti P, Rago T, Chiovato L, et al. Clinical features of patients with Graves' disease undergoing remission after antithyroid drug treatment. Thyroid. 1997;7(3):369-75. PMID: 9226205. https://doi.org/10.1089/thy.1997.7.369.

Matud MP. Gender differences in stress and coping styles. Pers Indiv Differ. 2004; 37(7):1401-15.

Davis K. A dubious equality: Men, women and cosmetic surgery. Sage Journal. 2002;81 (1):49–65. https://doi.org/10.1177/1357034X02008001003.

Published

2017-10-05

How to Cite

Mangelen, S. F., & Cunanan, E. (2017). Health-Related Quality of Life (HRQoL) of Adult Filipinos with Graves’ Disease cured by Radioiodine Therapy compared to those controlled by Antithyroid Drugs at University of Santo Tomas Hospital: A Pilot Study. Journal of the ASEAN Federation of Endocrine Societies, 32(2), 100. Retrieved from https://asean-endocrinejournal.org/index.php/JAFES/article/view/399

Issue

Section

Original Articles

Most read articles by the same author(s)